VAR 102
Alternative Names: VAR-102Latest Information Update: 07 May 2024
Price :
$50 *
At a glance
- Originator Varian Biopharmaceuticals
- Class Antineoplastics; Quinazolines
- Mechanism of Action Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 16 Apr 2024 Windtree Therapeutics has patent protection for protein kinase C inhibitors in USA and Europe prior to April 2024
- 16 Apr 2024 Windtree Therapeutics has patent protection for protein kinase C inhibitors to treat Hedgehog signaling pathway-related cancers in USA and Europe prior to April 2024
- 02 Apr 2024 Windtree Therapeutics acquires VAR 102 from Varian Biopharmaceuticals